Cytek (CTKB) Director Richard Chin Converts 6,107 RSUs

What Happened
Richard Chin, a director of Cytek Biosciences (CTKB), had 6,107 restricted stock units (RSUs) convert into 6,107 shares on August 18, 2026 (derivative transaction code M). The conversion was followed by a reported disposition of the same 6,107 shares at $0.00 — consistent with shares being surrendered or withheld (e.g., to satisfy tax withholding). No cash proceeds were reported.

Key Details

• Transaction date: August 18, 2026 (reported on Form 4 filed Aug 20, 2026). Filing appears timely.
• Transactions reported: conversion/exercise of 6,107 RSUs into 6,107 shares (Acquired), and a disposition of 6,107 shares at $0.00 (Disposed).
• Price/Proceeds: Acquired shown as N/A; Disposed at $0.00 — indicates no cash received by the insider on the disposition.
• Shares owned after transaction: Not specified in the provided filing.
• Relevant footnotes: F1 clarifies an RSU represents a contingent right to one share; F2 outlines the multi-year vesting schedule and shows an August 18, 2026 vesting tranche.
• Transaction code meaning: M = exercise or conversion of a derivative (here, RSU conversion). Disposition at $0.00 commonly reflects tax withholding or share surrender rather than an open-market sale.

Context
This appears to be a routine compensation/vesting event (RSU conversion with shares withheld to cover taxes), not an open-market purchase or sale that signals a change in investment sentiment. For retail investors, such conversions are normal for equity-compensated insiders and do not by themselves indicate a buy or sell decision in the market.